Michael S. Blaiss MD
Executive Medical Director, American College of Allergy, Asthma, and Immunology
Join to View Full Profile
1090 Windfaire PlRoswell, GA 30076
Phone+1 901-674-6075
Dr. Blaiss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Tulane UniversityFellowship, Allergy and Immunology, 1980 - 1982
University of TennesseeResidency, Pediatrics, 1978 - 1979- University of TennesseeResidency, Pediatrics, 1977 - 1977
University of Tennessee Health Science Center College of MedicineClass of 1976
Certifications & Licensure
GA State Medical License 2012 - 2025
TN State Medical License 1977 - 2018
MS State Medical License 2004 - 2016
American Board of Allergy and Immunology Allergy & Immunology
American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
- Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology
Publications & Presentations
PubMed
- Benefits of Epinephrine for Anaphylaxis Outweigh Potential Harm - A Safety Review.David I Bernstein, Michael Blaiss, Evan S Dellon, Karen Rance
The Journal of Allergy and Clinical Immunology. in Practice. 2025-04-18 - Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE).Jaclyn A Smith, Surinder S Birring, Michael S Blaiss, Lorcan McGarvey, Alyn H Morice
American Journal of Respiratory and Critical Care Medicine. 2025-03-05 - 4 citationsComparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE study.Eugene Bleecker, Michael Blaiss, Juby Jacob-Nara, Lynn Huynh, Mei Sheng Duh
The Journal of Allergy and Clinical Immunology. 2024-12-01
Press Mentions
A New Treatment for Severe Allergic Reactions — Without the NeedleAugust 19th, 2024- Leading Asthma Groups Tackle Definition of Clinical Remission in Treatment of AsthmaSeptember 11th, 2023
- U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for AdolescentsJanuary 25th, 2023
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
